Drugs / veltuzumab
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01147393 | Oct 2010 → Aug 2013 | follicular lymphoma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01101581 | May 2010 → Dec 2016 | diffuse large B-cell lymphoma | Gilead Sciences | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01279707 | Jan 2010 → Aug 2014 | B-cell acute lymphoblastic leukemia | Queen Mary University of London | Unknown | No outcome recorded |
| Phase 1/2 | NCT00989586 | Sep 2009 → Apr 2015 | lymphoma | Beth Christian | Completed | No outcome recorded |
| Phase 1/2 | NCT00546793 | Jan 2008 → Mar 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, large B-cell lymphoma, prolymphocytic leukemia | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00547066 | Nov 2007 → Nov 2011 | autoimmune thrombocytopenic purpura | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT00285428 | Sep 2004 → Oct 2007 | non-Hodgkin lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00596804 | Mar 2004 → Nov 2007 | non-Hodgkin lymphoma | Gilead Sciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01390545 Comparator | Aug 2011 → Oct 2012 | rheumatoid arthritis | Takeda | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | veltuzumab | “Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.” PMID 19451441 ↗ May 2009 |
| Known as | hA20 | “Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody” NCT00989586 ↗ |
| Known as | IMMU-106 | “Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody” NCT00989586 ↗ |
| Action | Deplete | “At all dose levels studied, B cells were depleted after the first infusion” PMID 19451441 ↗ May 2009 |
| Modality | Monoclonal antibody | “Low doses of the humanized anti-CD20 monoclonal antibody, veltuzumab” PMID 23829485 ↗ Jul 2013 |
| Route | Intravenous | “once weekly iv dosing for 4 weeks” NCT00285428 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL1743088 ↗ |